7427 Stock Overview
Engages in the development of drugs for the treatment of advanced and refractory cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Great Novel Therapeutics Biotech & Medicals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.70 |
| 52 Week High | NT$65.50 |
| 52 Week Low | NT$30.30 |
| Beta | -0.0030 |
| 1 Month Change | -4.66% |
| 3 Month Change | -11.50% |
| 1 Year Change | -33.60% |
| 3 Year Change | -17.32% |
| 5 Year Change | n/a |
| Change since IPO | -50.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7427 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -33.6% | 13.8% | 27.3% |
Return vs Industry: 7427 underperformed the TW Biotechs industry which returned 13.8% over the past year.
Return vs Market: 7427 underperformed the TW Market which returned 27.3% over the past year.
Price Volatility
| 7427 volatility | |
|---|---|
| 7427 Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 7427 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 7427's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 19 | Chia-Nan Chen | www.gntbm.com.tw |
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation.
Great Novel Therapeutics Biotech & Medicals Fundamentals Summary
| 7427 fundamental statistics | |
|---|---|
| Market cap | NT$1.43b |
| Earnings (TTM) | -NT$87.43m |
| Revenue (TTM) | NT$615.00k |
2,321x
P/S Ratio-16.3x
P/E RatioIs 7427 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7427 income statement (TTM) | |
|---|---|
| Revenue | NT$615.00k |
| Cost of Revenue | NT$243.00k |
| Gross Profit | NT$372.00k |
| Other Expenses | NT$87.80m |
| Earnings | -NT$87.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.00 |
| Gross Margin | 60.49% |
| Net Profit Margin | -14,216.10% |
| Debt/Equity Ratio | 0% |
How did 7427 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 15:52 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Great Novel Therapeutics Biotech & Medicals is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|